Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.

Blum, Claudine Angela; Schuetz, Philipp; Nigro, Nicole; Winzeler, Bettina; Arici, Birsen; Refardt, Julie; Urwyler, Sandrine Andrea; Rodondi, Nicolas; Blum, Manuel Raphael; Briel, Matthias; Mueller, Beat; Christ-Crain, Mirjam (2019). Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial. Clinical endocrinology, 91(3), pp. 374-382. Blackwell Scientific Publications 10.1111/cen.13907

Preview	Text Blum ClinEndocrinol 2018.pdf - Accepted Version Available under License Publisher holds Copyright. Download (607kB) | Preview
	Text Blum ClinEndocrinol(Oxf) 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (388kB)

OBJECTIVE

Glucocorticoids have been shown to improve outcome in community-acquired pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment response may vary. It is thus crucial to select patients with high likelihood to respond favorably. In critical illness, cosyntropin testing is recommended to identify patients in need for glucocorticoids. We investigated whether consyntropin testing predicts treatment response to glucocorticoids in CAP.

DESIGN

PREDEFINED SECONDARY ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL: PATIENTS: HOSPITALIZED PATIENTS WITH CAP: MEASUREMENTS: We performed 1μg cosyntropin tests in a randomized trial comparing prednisone 50mg for seven days to placebo. We investigated whether subgroups based on baseline and stimulated cortisol levels responded differently to glucocorticoids with regards to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into statistical models.

RESULTS

326 patients in the prednisone and 309 patients in the placebo group were evaluated. Neither basal cortisol nor a Δcortisol<250nmol/L after stimulation nor the combination of basal cortisol and Δcortisol predicted treatment response as measured by TTCS (all p for interaction>0.05). Similarly, we found no effect modification with respect to mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all p for interaction>0.05). However, glucocorticoids had a stronger effect on shortening length of hospital stay in patients with a baseline cortisol of ≥938 nmol/L (p for interaction=0.015).

CONCLUSIONS

Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 μg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for or against adjunct glucocorticoids in CAP should not be made depending on cortisol values or cosyntropin testing results. This article is protected by copyright. All rights reserved.

Interest & Impact

Downloads

334 since deposited on 07 Dec 2018
25 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item